Drug Trial Radar · NCT05353439
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
22
Actual
Start
Jul 27, 2022
Primary completion
Feb 11, 2026
Study completion Apr 21, 2026
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Apr 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement (recurrent). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tazemetostat in combination with topotecan and pembrolizumab may shrink or stabilize recurrent small cell lung cancer.
Conditions
- Extensive Stage Lung Small Cell Carcinoma
- Limited Stage Lung Small Cell Carcinoma
- Platinum-Resistant Lung Small Cell Carcinoma
- Platinum-Sensitive Lung Small Cell Carcinoma
- Recurrent Extensive Stage Lung Small Cell Carcinoma
- Recurrent Lung Small Cell Carcinoma
Interventions
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo collection of blood
Computed TomographyProcedure
Undergo CT scan
PembrolizumabBiological
Given IV
Tazemetostat HydrobromideDrug
Given PO
Topotecan HydrochlorideDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (Dose-escalation Cohort) of Tazemetostat in Combination With Topotecan and PembrolizumabTime frame: Up to 21 days (cycle 1)
- Incidence of Adverse Events (Expansion Cohort) by Type and Grade in the Expansion CohortTime frame: Up to 3 years
- Incidence of Grade 3 or Above Adverse Events by Type Related or Possibly Related to Study Treatment in the Dose Escalation CohortTime frame: Start of treatment through 30 days post last dose, an average of 112.33 days or 3.22 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Keck Medicine of USC Koreatown
Los Angeles, California
Los Angeles General Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Northwestern University
Chicago, Illinois
University of Kentucky/Markey Cancer Center
Lexington, Kentucky
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland
NCI - Center for Cancer Research
Bethesda, Maryland
Montefiore Medical Center-Einstein Campus
The Bronx, New York
Montefiore Medical Center - Moses Campus
The Bronx, New York
Wake Forest University at Clemmons
Clemmons, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.